Next 10 |
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire HONOLULU , Aug. 11, 2021 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and...
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities PR Newswire HONOLULU , May 14, 2021 /PRNewswi...
Cardax Reports 2020 Results - Net loss and operating expenses decreased vs. 2019 - ZanthoSyn® revenues decreased vs. 2019 - Company pursuing multiple funding opportunities - CHASE study recruitment suspended due to COVID-19 - COVID-19 clinical trial grant ap...
Cardax Reports Q3 2020 Results - Operating loss decreased vs. Q3 2019 - Net loss decreased vs. Q3 2019 - ZanthoSyn® revenues decreased vs. Q3 2019 - Cardax invited to submit updated federal grant application for COVID-19 clinical trial PR Newswire HONOLU...
HONOLULU , Aug. 14, 2020 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) reported its Q2 2020 results. Highlights: Financial Results . Net operating loss from the same quarter last year decreased from $1,049,412 in Q2 2019 to $789,032 in Q2 2020, primarily attributed to a decrease...
HONOLULU , May 15, 2020 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) reported its Q1 2020 results. Highlights: Financial Results . Net losses from the same quarter last year decreased 11.7%, from $1,135,420 in Q1 2019 to $1,002,868 in Q1 2020, primarily attributed to a decrease in s...
HONOLULU , March 30, 2020 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) reported its 2019 results. Highlights: CHASE Clinical Trial . On September 23, 2019 , the Company announced findings from the pre-specified interim review of its ongoing CHASE ( C ardiovascular H ealth A st...
HONOLULU , March 20, 2020 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) today released a white paper outlining the potential role of astaxanthin in the treatment of coronavirus disease and is seeking strategic collaborations to further develop astaxanthin for COVID-19. The paper focuses on th...
HONOLULU , Jan. 14, 2020 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) today announced it will effect a 200-for-1 reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Amendment to the Company's Certificate of Incorporation filed with the Secretar...
HONOLULU , Nov. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019. Highlights were as follows: CHASE Clinical Trial . On September 23, 2019 , the Company announced results from the pre-specified interim review of its ongoing CHAS...
News, Short Squeeze, Breakout and More Instantly...
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire HONOLULU , Aug. 11, 2021 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and...
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities PR Newswire HONOLULU , May 14, 2021 /PRNewswi...
Cardax Reports 2020 Results - Net loss and operating expenses decreased vs. 2019 - ZanthoSyn® revenues decreased vs. 2019 - Company pursuing multiple funding opportunities - CHASE study recruitment suspended due to COVID-19 - COVID-19 clinical trial grant ap...